Current management of pain
==========================

The control of pain, a complex and subjective experience, is critical to clinical success in caring for patients. Opioids such as oxycodone, methadone and morphine are the recommended therapy by the World Health Organization and the European Association for Palliative Care for moderate to severe pain \[[@B1],[@B2]\]. However, the use of opioids in pain management requires careful dose escalation and empirical adjustments based on clinical response and the presence of side effects or adverse drug reactions (ADRs). Unfortunately, successful pain management treatment - defined as adequate analgesia without excessive adverse effects \[[@B3]\] - can be challenging \[[@B4]\]. Unpleasant opioid side effects, such as nausea, vomiting, constipation and sedation, are common and can lead to absence from work, poor performance at work and the resulting risk of job loss, and a diminished quality of life. The most serious issues involve the risk of sedation, depression of respiration and unintentional death due to inability or poor ability to metabolize the medications successfully. An individual\'s genetic makeup may predispose the patient to these adverse effects and reduced efficacy. Pharmacogenomic approaches offer insight into the genetic variables that can affect a drug\'s uptake, transport, activation of its target, metabolism, interaction with other medications and excretion. The use of pharmacogenomics in patients requiring pain management can lead to more efficient opioid selection, dose optimization and minimization of ADRs to improve patient outcome.

Clinically relevant candidate genes for pain management
=======================================================

Cellular transporters control the uptake, distribution and elimination of drugs. P-glycoprotein is an efflux transporter also called adenosine triphosphate-binding cassette, subfamily B, member 1 (ABCB1) or multidrug resistance 1 (MDRD1) \[[@B5]\]. It is expressed in hepatic, intestinal and renal epithelial cells and also on the luminal side of endothelial cells in the blood-brain barrier, and it is a major determinant of the pharmacokinetics and pharmacodynamics of several opioids (such as morphine, methadone and fentanyl) commonly used to treat pain \[[@B5]\]. Genetic variants (such as 3435C \> T) in P-glycoprotein have been associated with variability of pain relief in cancer patients treated with morphine \[[@B6]\]. The analgesic effects of morphine are mediated by its interaction at the μ-opioid receptor located in the central nervous system (CNS). P-glycoprotein can limit the concentration of pain management drugs, such as morphine, in the brain because it actively pumps drugs out of the CNS. As a result, homozygous carriers of the 3435C \> T variant (TT carriers) experience greater pain relief than heterozygous (CT) or homozygous wild-type (CC) carriers, presumably because higher concentrations of morphine can be achieved in the CNS \[[@B6]\]. Table [1](#T1){ref-type="table"} lists the clinically relevant pharmacogenomic targets for pain management.

###### 

Clinically relevant pharmacogenomic targets for pain management

  Gene       Variant                  Analgesics affected            Consequence of genetic variation
  ---------- ------------------------ ------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------
  *ABCB1*    3435C\>T                 Morphine                       Homozygous variants cause increased efficacy
  *CYP2D6*   1846G\>A, 2549A\>del     Codeine, oxycodone, tramadol   Poor metabolizers (PM; variants) have more adverse drug reactions and less efficacy
  *UGT2B7*   -840G\>A, 802C\>T; \*2   Morphine                       Homozygous variants require lower doses of morphine for efficacy; *UGT2B7*\*2 variants have less side effects (nausea) with morphine
  *COMT*     1947G\>A, (Rs4680)       Morphine                       Homozygous variants have a three- to fourfold decrease in COMT activity; wild-type patients require higher doses of morphine for efficacy than variant patients
  *OPRM1*    118A\>G                  Morphine, M6G                  Homozygous variants cause decreased effectiveness and increased dose requirements

The cytochrome P450 (CYP) system is responsible for metabolizing a wide range of therapeutic agents used for pain relief. *CYP2D6*is especially important for the activation or inactivation of several opioids used to treat pain, including codeine, oxycodone and tramadol \[[@B7]\]. Typically, the genetic variability of CYP can be grouped into four phenotypes: ultrarapid metabolizers (UM), extensive metabolizers (EM), intermediate metabolizers (IM) and poor metabolizers (PM). UM-classified patients typically contain multiple copies of a gene, which results in an increase in drug metabolism \[[@B8]\]. EM-classified patients are characteristic of the normal population and have a single wild-type copy of the gene, whereas IM-classified patients show decreased enzymatic activity and PM-classified patients have no detectable enzymatic activity \[[@B8]\]. Codeine is a prodrug that requires demethylation to its active metabolite morphine by *CYP2D6*before it can exert an analgesic effect. As a result, *CYP2D6*PM-classified patients experience ineffective analgesia and increased side effects from the parent drug (codeine) \[[@B7]\]. On the other hand, *CYP2D6*UM-classified patients prescribed codeine for pain management generate extensive concentrations of morphine, which can lead to ADRs \[[@B9]\].

Tramadol, another opioid commonly used for pain management, produces analgesia by the synergistic action of its two enantiomers and their metabolites \[[@B7]\]. Tramadol undergoes metabolism by *CYP2D6*to an active metabolite (*O*-desmethyl tramadol), which has greater affinity for the μ-opioid receptor than does the parent compound \[[@B7]\]. Genetic variations in *CYP2D6*have been shown to account for some of the variable pain response in the post-operative period because the *CYP2D6*activity has a clinically relevant impact on the level of analgesia mediated by the μ-opioid receptor \[[@B10]\].

Another important genetic target is uridine diphosphate-glucuronosyltransferase 2B7 (*UGT2B7*), which metabolizes morphine to morphine 3-glucuronide (M3G) and morphine 6-glucuronide (M6G). The latter has a higher analgesic potency than the parent compound \[[@B11]\]. Morphine is commonly used to control moderate and severe pain associated with sickle cell disease. Darbari *et al.*\[[@B12]\] showed that the presence of the *UGT2B7*-840G \> A genotypes (GG and GA) were associated with lower M3G:morphine and M6G:morphine ratios than AA genotypes. As a result, genetic polymorphisms in *UGT2B7*have been shown to decrease the hepatic clearance of morphine, which translates into lower dosage requirements of morphine \[[@B12]\]. In another study \[[@B13]\], the *UGT2B7\*2*polymorphism (802C \> T) was also shown to be associated with the frequency of morphine-induced ADRs (nausea) in cancer patients. The authors showed that the frequency of nausea was higher in patients without the *UGT2B7\*2*allele \[[@B13]\].

Furthermore, the efficacy of opioid analgesia can be enhanced by the co-administration of catecholamines, which are involved in the modulation of pain \[[@B14]\]. Catechol-*O*-methyltransferase (COMT) is responsible for the inactivation of catecholamines (dopamine, adrenaline and norepinephrine). As a result, genetic variability in the *COMT*gene can contribute to differences in pain sensitivity and response to analgesics. It has been shown that a common variant allele (1947G \> A; Rs4680) results in a three- to fourfold reduction in *COMT*enzyme activity \[[@B15]\]. Homozygous wild-type (GG) cancer patients required higher doses of morphine to control pain than heterozygous or homozygous variant (AA) alleles \[[@B16],[@B17]\].

Finally, the μ-opioid receptor encoded by the opioid-receptor-like 1 (*OPRM1*) gene is the primary site of action for most of the commonly used opioids. The 118A \> G polymorphism in this gene results in less effective opioid analgesia, as reported with cancer patients with homozygous variant alleles (GG) who required higher morphine doses for pain relief than homozygous wild-type (AA) participants \[[@B18]\]. In another study \[[@B19]\], Chou *et al.*investigated the correlation between the 118A \> G polymorphism and patient-controlled morphine consumption in patients undergoing total knee arthroplasty. Patients who were homozygous variants (GG) consumed approximately 60% more morphine than patients who were heterozygous or homozygous wild-type (AA) during the first 48-hour post-operative period. Patient demographics, reported pain and other factors did not differ between the genotype groups. In a similar study \[[@B20]\], women who had homozygous variants for the 118A \> G polymorphism required 30% more morphine to achieve adequate pain control than those who were wild type (AA) during the first 24 hours after a total abdominal hysterectomy. Finally, a significant relationship between the degree of pain relief and the 118A \> G genotypes was shown in cancer patients being treated with morphine over the first 2 months of therapy \[[@B6]\]. In the first 7 days of morphine treatment, patients homozygous for the wild-type allele (AA) had more pronounced decrease in pain from baseline than those who were homozygous variants (GG), whose response was almost undetectable \[[@B6]\].

Limitations and future directions of pharmacogenomics for pain management
=========================================================================

Genomic variations clearly influence pain sensitivity, the likelihood of developing chronic pain and the response to pharmacotherapy for the management of pain \[[@B21],[@B22]\]. Pharmacogenomic polymorphisms are definitely important in the interindividual variability in the analgesic effects and occurrence of ADRs of commonly used medications prescribed for pain management, but genetic factors will provide only a partial answer to the interindividual variability observed. Other factors, including biological variations (ethnicity, age and gender), environmental factors (smoking status), co-morbidity and co-medications (potential for drug-drug interactions) must be considered along with the genetic variations because together they all affect the pharmacokinetics and pharmacodynamics of medications used for pain management. Additional studies are also needed to characterize the combined effects of multiple genes along with demographic and clinical variables in selecting the appropriate opioid and predicting the appropriate opioid dose in patients with pain. Large, randomized prospective studies are needed to develop appropriate dosing or treatment algorithms to facilitate the use of genotyping information appropriately by physicians. Furthermore, the continued development of regulator-approved genotyping assays to identify these variant alleles will allow greater access to this information to aid in day-to-day clinical decisions for acute and chronic pain management. The benefits of patient care and safety will result in the incorporation of this knowledge into the standard of care for anesthesiologists and pain management physicians. In the near future, pharmacogenomic approaches in pain management could lead to individualized therapy to best select the appropriate analgesic from the onset to provide sustained efficacy with the lowest side effect profile.
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